TP53-mutant acute myeloid leukemia/myelodysplastic neoplasms (AML/MDS) are distinct clinicogenomic entities characterized by chemotherapy resistance, high relapse rates, and poor survival. Here, TP53 is linked to myelodysplastic syndrome.